PRN Profound Medical Corp.
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.…
Industry Peers
Medical DevicesKey Statistics
About Profound Medical (TSE: PRN)
›
Profound Medical (TSE: PRN) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 162 employees.
The shares were at 9.540 CAD on 19 November 2026, up 11.2% over 52 weeks. Its 52-week range is 6.520 CAD to 12.40 CAD: the price is 23.1% below the high and 46.3% above the low.
Its market capitalisation is 349.42M CAD.
Profound Medical reports return on equity of -64.1%, an operating margin of -145.1% and revenue up 85.9% year over year.
It holds more cash than debt, a net cash position of 25.98M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 4 March 2027.